



Regulated Information

Oxurion Receives Transparency Notification from Atlas Special Opportunities II LLC

Leuven, BELGIUM – July 15, 2025 – 06:00 PM CET - Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, today announced that, pursuant to Belgian Transparency legislation¹ it has received a transparency notification as follows:

Oxurion received a transparency notification on July 15, 2025, from Atlas Special Opportunities II, LLC indicating that as of July 14, 2025, it held 2,751,917 shares of the then outstanding 12,428,021 shares, and therefore crossed under the threshold (25%) by virtue of the selling of voting securities.

About Oxurion

Oxurion NV (Euronext Brussels: OXUR) is a biopharmaceutical group in transition, combining therapeutic innovation with technologies applied to clinical research. Through its rapidly expanding technology division, Oxurion is building integrated expertise around clinical data, with the ambition to accelerate, secure, and transform the processes involved in developing new treatments. The Group's headquarters are based in Leuven, Belgium. More information is available at www.oxurion.com.

Important information about forward-looking statements

Certain statements in this press release may be considered "forward-looking". Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the Company's Annual Report. This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of Oxurion in any jurisdiction. No securities of Oxurion may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. state securities laws.

For further information please contact:

Oxurion NV
Pascal Ghoson
Chief Executive Officer
Pascal.ghoson@oxurion.com

1. Article 14, first paragraph, of the Law of 2 May 2007 on disclosure of major holdings.

ANNEX 1

	L SERVICES AND AUTHORITY		Transpare Form TR-1 BE PART I	ncy notifica	ition		
1) Status of the notification							
	Final						
2) Issuer							
Name							
Identification numbe	n 0881-620-924						
3) Reason for the notification	<u>n</u>						
	Acquisition or disposal of voting	securities or voting righ	its				+
4) Notification by							
	A person that notifies alone						+
5) Persons subject to the no	diffication requirement						_
3) Persons subject to the ne	direatori requirement						
	Name		Address (for legal entities)				
	Atlas Special Opportunities II L	rc	2500 Westchester Ave	nue, Sulte 401, Purcha	se, NY 10577		+
6) Persons that dispose of v	voting rights (only to be file	d in if art. 7 of the Law	applies)				
	Name			Address (for legs	d antificati		
	realing						
	Please continue entering the	Information in page II o	oncoming the				
· ·	persons referred to In Section	ns 5 and 6	Aicerting the	Part II			
7) Date on which the thresh	old is crossed						
		14/07/2025	(DD/MMYYYY)				
8) Threshold that is crossed	(in %)						
		25					
•	If the holding has fallen below	w the lowest threshold	i, you have the option	n of not entering any	numbers in Section	10	
9) Denominator							
		12,428,021					
0	Please enter the denominator	r before filling in the d	lata				
10) Notified details							
A) Voting rights	Previous notification]			
Holders of voting rights	# of voting r	ngnts	# of vot	ng rights Not linked to the	% of vot	Not linked to the	1
Attas Special Opportunities II LLC	3,524,93	14	2,751,917	securities		securities	+
							4 📖

Start with "groups" of holders. Add subtotals with Σ , and then finish with the persons who are "alone". For groups, start with the utilimate controlling natural person or legal entity. The totals, subtotals and % will be updated once you have clicked on <CALCULATE>.

2,751,917

TOTAL

0.00%

22.14%

B) Equivalent financial instruments	After the transaction										
Holders of equivalent financial instruments	Type of financial instrument	Expiration date	Exercise period or date	# of voting rights that may be acquired if the instrument is exercised	% of voting rights	Settlement					
						4					
	TOTAL			0	0.00%						
The rorals will be updated once you have clicked on <calculate></calculate>											
	TOTAL (A & B)			# of voting rights	% of voting rights						
	-				22.14%						
11) Full chain of controlled undertakings through which the holding is effectively held, if applicable											
	Attas Special Opportunities II LLC is not a controlled er	ntity.									
12) In case of proxy voting for	or only one GM	Ī		ī	ı	(ролммлот)					
Holder		will cease to hold / will hold again	0		voting rights as of						
13) Additional information											
04 July 2025 (with settlement date on 0	8 July 2025), Atlas Special Opportunities II LLC sold 25	2 886 shares in Oxur	fon NV. as a result of v	which its shareholdir	o decreased to 3.524	934 shares (= 28.36%					
nominator = 12,428,021). 10 July 2025 (with settlement date on 14 July 2025), Atlas Special Opportunities II LLC sold 361,664 shares in Oxurion NV, as a result of which its shareholding decreased to 2,751,917 shares (= 22.14% nominator = 12,428,021).											
Done at N On Name & capacity P		DDIMMYYYY)	Signature	Patrick Usu	u						
					s, the unsigned form in p_fin@fsma.be. You c						

OR if you have MS Outlook at your disposal via the "Save & Send" button.

In addition, a signed copy in <u>PDF</u> format should also be transmitted.